Raffaele Landolfi

Raffaele Landolfi

Auto-generated profile, based on publicly available information

Raffaele Landolfi

Catholic University School of Medicine, Rome, Italy

Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2005 in New England Journal of Medicine
Verified
Journal Article
Closed access
CPCarlo Patrono
Carlo Patrono
LRLuis A. García Rodríguez
Luis A. García Rodríguez
RLRaffaele Landolfi
Raffaele Landolfi
CBColin Baigent
Colin Baigent
This review considers the role of low-dose aspirin for the prevention of atherothrombosis, discussing the molecular mechanism of action of aspirin as well as clinical and epidemiologic studies of aspirin as an antiplatelet agent, with special emphasis on the benefits and risks in different patient populations.

8 January 2004 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
RLRaffaele Landolfi
Raffaele Landolfi
RMRoberto Marchioli
Roberto Marchioli
JKJack Kutti
Jack Kutti
HGHeinz Gisslinger
Heinz Gisslinger
GTGianni Tognoni
Gianni Tognoni
TBTiziano Barbui
Tiziano Barbui
The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial. We enrolled 518 patients with polycythemia vera, no clear indication for aspirin treatment, and no contraindication to such treatment in a double-blind, placebo-controlled, randomized trial to assess the safety and efficacy of prophylaxis with low-dose aspirin (100 mg daily). The two primary end points were the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes. The mean duration of follow-up was about three years. Treatment with aspirin, as compared with placebo, reduced the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes (relative risk, 0.41; 95 percent confidence interval, 0.15 to 1.15; P=0.09) and the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes (relative risk, 0.40; 95 percent confidence interval, 0.18 to 0.91; P=0.03). Overall mortality and cardiovascular mortality were not reduced significantly. The incidence of major bleeding episodes was not significantly increased in the aspirin group (relative risk, 1.62; 95 percent confidence interval, 0.27 to 9.71). Low-dose aspirin can safely prevent thrombotic complications in patients with polycythemia vera who have no contraindications to such treatment.

1 April 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RMRoberto Marchioli
Roberto Marchioli
GFGuido Finazzi
Guido Finazzi
RLRaffaele Landolfi
Raffaele Landolfi
JKJack Kutti
Jack Kutti
HGHeinz Gisslinger
Heinz Gisslinger
TBTiziano Barbui
Tiziano Barbui
Purpose: The clinical course of polycythemia vera is often complicated by thrombosis as well as by the possible transition to myeloid metaplasia with myelofibrosis or acute myeloid leukemia. The aim of this study was to assess the rate of these complications in subjects receiving currently recommended treatments. Patients and Methods: Overall, 1,638 patients from 12 countries were enrolled onto a large, prospective multicenter project aimed at describing the clinical history of polycythemia vera for the following outcomes: survival, the cumulative rate of cardiovascular death and thrombosis, the cumulative rate of leukemia, myelodysplasia, and myelofibrosis. The mean duration of the disease at entry and the duration of the follow-up were 4.9 and 2.7 years, respectively. Results: The overall mortality rate of 3.7 deaths per 100 persons per year resulted from a moderate risk of cardiovascular death and a high risk of death from noncardiovascular causes (mainly hematologic transformations). Age older than 65 years and a positive history of thrombosis were the most important predictors of cardiovascular events. Antiplatelet therapy, but not cytoreductive treatment, was significantly associated with a lower risk of cardiovascular events. We found a consistent association between age and risk of leukemia, and between duration of the disease with risk of myelofibrosis. Conclusion: The European Collaboration on Low-Dose Aspirin in Polycythemia Vera study documents that large international collaborative studies are feasible in this field, in which few epidemiologic data are available. The persistently high mortality rate from hematologic malignancies characterizes the unmet therapeutic need of polycythemic patients and suggests a priority for future studies in this disease.

1 October 2009 in Journal of Hepatology
Verified
Journal Article
Closed access
MZMaria Assunta Zocco
Maria Assunta Zocco
ESEnrico Di Stasio
Enrico Di Stasio
RCRaimondo De Cristofaro
Raimondo De Cristofaro
MNMarialuisa Novi
Marialuisa Novi
MAMaria Elena Ainora
Maria Elena Ainora
AGAntonio Gasbarrini
Antonio Gasbarrini

1 April 2005 in Blood
Verified
Journal Article
Closed access
PDF file
GFGuido Finazzi
Guido Finazzi
VCVanesa Caruso
Vanesa Caruso
RMRoberto Marchioli
Roberto Marchioli
GCGiovanni Capnist
Giovanni Capnist
TCTeodoro Chisesi
Teodoro Chisesi
TBTiziano Barbui
Tiziano Barbui
Progression to acute myeloid leukemia/myelodysplastic syndromes (AML/MDS) is a possible evolution of polycythemia vera (PV), but whether some patients are at increased natural risk for this complication and how much the contribution of pharmacologic cytoreduction can affect the natural course of the disease remain uncertain. The European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) prospective project included 1638 patients with PV. AML/MDS was diagnosed in 22 patients after a median of 2.5 years from recruitment in the study and a median of 8.4 years from the diagnosis of PV. Variables associated with progression to AML/MDS were assessed using different models of multivariate analysis. Older age was confirmed as the main independent risk factor (hazard ratio [HR], 4.30; 95% confidence interval [95% CI], 1.16-15.94; P = .0294), whereas overall disease duration failed to reach statistical significance (more than 10 years: HR, 1.91; 95% CI, 0.64-5.69; P = .2466). Exposure to P32, busulphan, and pipobroman (HR, 5.46; 95% CI, 1.84-16.25; P = .0023), but not to hydroxyurea (HU) alone (HR, 0.86; 95% CI, 0.26-2.88; P = .8021), had an independent role in producing an excess risk for progression to AML/MDS compared with treatment with phlebotomy or interferon.

1 September 1998 in The Lancet
Verified
Journal Article
Closed access
AGAntonio Gasbarrini
Antonio Gasbarrini
FFFrancesco Franceschi
Francesco Franceschi
RTRaffaele Tartaglione
Raffaele Tartaglione
RLRaffaele Landolfi
Raffaele Landolfi
PPPaolo Pola
Paolo Pola
GGGiovanni Gasbarrini
Giovanni Gasbarrini